Nektar Therapeutics buy bundfuture
Start price
09.03.20
/
50%
€15.59
Target price
01.04.20
€16.00
Performance (%)
0.97%
End price
01.04.20
€15.74
Summary
This prediction ended on 01.04.20 with a price of €15.74. The BUY prediction by bundfuture for Nektar Therapeutics closed nearly unchanged. bundfuture has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Nektar Therapeutics | 19.121% | 19.121% | 113.723% | -91.029% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |